MaxCyte, Inc.

MXCT ·Healthcare, Diagnostics & Research, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-44.6M $-41.1M $-37.9M $-23.6M $-19.1M $-11.8M $-12.9M
Depreciation & Amortization $4.3M $4.3M $4.2M $2.7M $1.4M $1.0M $613.5K
Depreciation $4.3M $4.3M — — — — —
Amortization $53.0K — — — — — —
Stock-Based Compensation $9.2M $13.1M $14.0M $11.8M $8.0M $2.5M $1.8M
Net Cash from Operating Activities $-34.4M $-27.6M $-21.7M $-14.8M $-10.7M $-8.8M $-8.8M
Investing Activities
Capital Expenditures $1.8M $1.7M $3.7M $18.5M $3.8M $2.1M $1.3M
Business Acquisitions $1.8M — — — — — —
Net Cash from Investing Activities $25.9M $6.9M $55.0M $-24.8M $-195.0M $-16.6M $454.5K
Financing Activities
Dividends Paid — — — — — — —
Stock Repurchases — — — — — — —
Net Cash from Financing Activities $656.0K $2.1M $2.1M $2.9M $234.7M $28.9M $12.3M
Net Change in Cash $-7.8M $-18.6M $35.4M $-36.7M $29.0M $3.5M $4.0M
Free Cash Flow $-36.2M $-29.3M $-25.4M $-33.3M $-14.5M $-10.9M $-10.1M